Formulation: A solid
Formal Name: N-(1-oxopentyl-2,2,3,3,4,4,5,5,5-d9)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C24H20D9N5O3
Formula Weight: 444,6
Shelf life (days): 1460
CAS Number: 1089736-73-1
Notes: Valsartan-d9 is intended for use as an internal standard for the quantification of valsartan (Item No. 14178) by GC- or LC-MS. Valsartan is a nonpeptide antagonist of the angiotensin II type 1 (AT1) receptor (IC50 = 2.7 nM).{21001} It is 20,000-fold selective for AT1 over AT2 and, unlike some other AT receptor antagonists, does not alter peroxisome proliferator-activated receptor γ (PPARγ) activity in vitro.{20999} In vivo, valsartan (30 mg/kg) increases cardiac output and reduces left ventricular fibrosis in a model of heart failure with reduced ejection fraction in mice with streptozotocin-induced diabetes.{42153} Formulations containing valsartan have been used in the treatment of hypertension and heart failure.{13660,20999,12999}